Table 2.
Logistic regression models for development of any stage skin or gut aGVHD
| Target organ | Factor | aGVHD/patients at risk |
Odds ratio (95% CI) | p Value |
|---|---|---|---|---|
| Skin aGVHD | ||||
| Low CLA+ Tregs | 27/49 | 1 | 0.020 | |
| High CLA+ Tregs* | 6/25 | 0.27 (0.09–0.81) | ||
| Myeloablative | 20/45 | 1 | 0.430 | |
| Reduced intensity | 13/29 | 0.63 (0.20–1.97) | ||
| Related donor | 19/50 | 1 | 0.750 | |
| Unrelated donor | 14/24 | 1.32 (0.24–7.36) | ||
| Peripheral blood stem cells | 21/55 | 1 | 0.300 | |
| Bone marrow or cord blood | 12/19 | 2.53 (0.44–14.6) | ||
| Gut aGVHD | ||||
| Low α4β7+Tregs | 41/55 | 1 | 0.011 | |
| High α4β7+ Tregs† | 9/19 | 0.20 (0.06–0.69) | ||
| Myeloablative | 33/45 | 1 | 0.145 | |
| Reduced intensity | 17/29 | 0.41 (0.12–1.36) | ||
| Related donor | 32/50 | 1 | 0.716 | |
| Unrelated donor | 18/24 | 1.43 (0.21–9.69) | ||
| Peripheral blood stem cells | 36/55 | 1 | 0.833 | |
| Bone marrow or cord blood | 14/19 | 1.24 (0.17–9.16) |
*
High CLA+ Tregs: CLA+ Tregs/Tregs ≥3.25%.
†
High α4β7+ Tregs: α4β7+ Tregs/Tregs ≥21.8%.